Literature DB >> 35068600

Alterations of the Gut Microbiome in Recurrent Malignant Gliomas Patients Received Bevacizumab and Temozolomide Combination Treatment and Temozolomide Monotherapy.

Junwei Zhu1, Jun Su2.   

Abstract

This case-control study explored compositions of gut microbiome in recurrent malignant gliomas patients who had received bevacizumab and Temozolomide combination treatment and Temozolomide monotherapy. We investigated gut microbiota communities in feces of 29 recurrent malignant gliomas patients received combination treatment with bevacizumab and Temozolomide (Group 1) and monotherapy with Temozolomide alone (Group 2). We took advantage of the high-throughput Illumina Miseq sequencing technology by targeting the third and fourth hypervariable (V3-V4) regions of the 16S ribosomal RNA (rRNA) gene. We found that the structures and richness of the fecal microbiota in Group 1 were different from Group 2 with LEfSe analysis. The fecal microbiota in both Group 1 and Group 2 were mainly composed by Firmicutes, Proteobacteria, Bacteroidetes and Actinobacteria. However, Group 1 patients had higher relative abundance of Firmicutes, Bacteroidetes, Actinobacteria and lower relative abundance of Bacteroidetes and Cyanobacteria in their fecal microbiota than that in Group 2 patients. To evaluate bevacizumab involved post-treatment state of the fecal microbiota profile, we used random forest predictive model and ensembled decision trees with an AUC of 0.54. This study confirmed that the gut microbiota was different in recurrent malignant gliomas patients received the combination therapy of bevacizumab and Temozolomide compared with Temozolomide monotherapy. Our discover can help better understand the influence of bevacizumab related treatment on recurrent malignant gliomas patients. Therefore, this finding may also support the potentially therapeutic options for recurrent malignant gliomas patients such as fecal microbiota transplant. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12088-021-00962-2. © Association of Microbiologists of India 2021.

Entities:  

Keywords:  16S rRNA gene; Bevacizumab; Gut microbiota; Recurrent malignant glioma; Temozolomide

Year:  2021        PMID: 35068600      PMCID: PMC8758882          DOI: 10.1007/s12088-021-00962-2

Source DB:  PubMed          Journal:  Indian J Microbiol        ISSN: 0046-8991            Impact factor:   2.461


  21 in total

Review 1.  Management of glioblastoma: State of the art and future directions.

Authors:  Aaron C Tan; David M Ashley; Giselle Y López; Michael Malinzak; Henry S Friedman; Mustafa Khasraw
Journal:  CA Cancer J Clin       Date:  2020-06-01       Impact factor: 508.702

2.  Modulating gut microbiota to treat cancer.

Authors:  Christopher H Woelk; Alexandra Snyder
Journal:  Science       Date:  2021-02-05       Impact factor: 47.728

3.  Oncological relevance of gut and urine microbiomes

Authors:  Csilla Oláh; Melinda Váradi; Orsolya Horváth; Péter Nyirády; Tibor Szarvas
Journal:  Orv Hetil       Date:  2021-04-02       Impact factor: 0.540

Review 4.  Diet-Microbiota-Brain Axis in Alzheimer's Disease.

Authors:  Halle J Kincaid; Ravinder Nagpal; Hariom Yadav
Journal:  Ann Nutr Metab       Date:  2021-04-27       Impact factor: 3.374

Review 5.  Psoriasis and Gut Microbiome-Current State of Art.

Authors:  Karina Polak; Beata Bergler-Czop; Michał Szczepanek; Kamila Wojciechowska; Aleksandra Frątczak; Norbert Kiss
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

Review 6.  Emerging applications of bacteria as antitumor agents.

Authors:  Vipin Chandra Kalia; Sanjay K S Patel; Byung-Kwan Cho; Thomas K Wood; Jung-Kul Lee
Journal:  Semin Cancer Biol       Date:  2021-05-11       Impact factor: 17.012

7.  Antibiotic-associated dysbiosis affects the ability of the gut microbiota to control intestinal inflammation upon fecal microbiota transplantation in experimental colitis models.

Authors:  Jacopo Troisi; Federica Facciotti; Francesco Strati; Meritxell Pujolassos; Claudia Burrello; Maria Rita Giuffrè; Georgia Lattanzi; Flavio Caprioli
Journal:  Microbiome       Date:  2021-02-06       Impact factor: 14.650

Review 8.  Targeting Protein Kinase C in Glioblastoma Treatment.

Authors:  Noelia Geribaldi-Doldán; Irati Hervás-Corpión; Ricardo Gómez-Oliva; Samuel Domínguez-García; Félix A Ruiz; Irene Iglesias-Lozano; Livia Carrascal; Ricardo Pardillo-Díaz; José L Gil-Salú; Pedro Nunez-Abades; Luis M Valor; Carmen Castro
Journal:  Biomedicines       Date:  2021-04-04

9.  Gut microbiota accelerates cisplatin-induced acute liver injury associated with robust inflammation and oxidative stress in mice.

Authors:  Shenhai Gong; Yinglin Feng; Yunong Zeng; Huanrui Zhang; Meiping Pan; Fangjie He; Rong Wu; Jingrui Chen; Jiuling Lu; Siyou Zhang; Songhua Yuan; Xia Chen
Journal:  J Transl Med       Date:  2021-04-13       Impact factor: 5.531

Review 10.  Gut Microbiota in Cancer Immune Response and Immunotherapy.

Authors:  Cheng-Bei Zhou; Yi-Lu Zhou; Jing-Yuan Fang
Journal:  Trends Cancer       Date:  2021-03-02
View more
  1 in total

1.  Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells.

Authors:  Jonas Feldheim; Almuth F Kessler; Julia J Feldheim; Ellina Schulz; David Wend; Lazaros Lazaridis; Christoph Kleinschnitz; Martin Glas; Ralf-Ingo Ernestus; Sebastian Brandner; Camelia M Monoranu; Mario Löhr; Carsten Hagemann
Journal:  Int J Mol Sci       Date:  2022-05-07       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.